| |
著者: Maruyama T, Takashima H, Abe M.
雑誌名: Expert Opin Pharmacother. 2020 Jul;21(10):1219-1240. doi: 10.1080/14656566.2020.1746272. Epub 2020 Apr 13.
Abstract/Text
INTRODUCTION: Hypertension is highly prevalent in patients with end-stage kidney disease on hemodialysis and is often not well controlled. Blood pressure (BP) levels before and after hemodialysis have a U-shaped relationship with cardiovascular and all-cause mortality. Although antihypertensive drugs are recommended for patients in whom BP cannot be controlled appropriately by non-pharmacological interventions, large-scale randomized controlled clinical trials are lacking.
AREAS COVERED: The authors review the pharmacotherapy used in hypertensive patients on dialysis, primarily focusing on reports published since 2000. An electronic search of MEDLINE was conducted using relevant key search terms, including 'hypertension', 'pharmacotherapy', 'dialysis', 'kidney disease', and 'antihypertensive drug'. Systematic and narrative reviews and original investigations were retrieved in our research.
EXPERT OPINION: When a drug is administered to patients on dialysis, the comorbidities and characteristics of each drug, including its dialyzability, should be considered. Pharmacological lowering of BP in hypertensive patients on hemodialysis is associated with improvements in mortality. β-blockers should be considered first-line agents and calcium channel blockers as second-line therapy. Renin-angiotensin-aldosterone system inhibitors have not shown superiority to other antihypertensive drugs for patients on hemodialysis.
PMID 32281890 Expert Opin Pharmacother. 2020 Jul;21(10):1219-1240. doi: 10.1080/14656566.2020.1746272. Epub 2020 Apr 13.
|
